Futoshi Iioka
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Futoshi Iioka has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Hitoshi Ohno
Tenri Institute of Medical Research, Tenri Hospital
8 shared publications Atsuko Okumura
D Laboratory of Cytogenetics, Tenri Institute of Medical Research , Tenri , Japan
7 shared publicationsHitoshi Ohno
Departments of Hematology Tenri Hospital Tenri Japan
7 shared publicationsChiyuki Kishimori
Tenri Inst Med Res, Tenri, Nara, Japan
5 shared publicationsGen Honjo
Departments of Diagnostic Surgical Pathology Tenri Hospital Tenri Japan
5 shared publicationsKatsuhiro Fukutsuka
Tenri Inst Med Res, Tenri, Nara, Japan
5 shared publications
Latest Publications
- Open Access
- 16 October 2021
- Published by Springer Nature in Diabetology International
- Vol. 13 (2) , 456-460
Production of insulin antibody associated with relapsed hodgkin’s lymphoma
A 72-year-old man with type 2 diabetes mellitus with good glucose control for 20 years and maintained on oral hypoglycaemic agents was diagnosed with Hodgkin’s Lymphoma (HL) and started on insulin glargine for glycaemic control. Despite increased doses of insulin, his blood glucose levels went up dramatically. The anti-insulin antibody test proved to be positive, and Scatchard plot analysis showed 2 binding sites with relatively low-affinity constants: K1 = 0.0032, K2 = 0.0002 (108/M); and high binding capacities: R1 = 98.4, R2 = 372 (10−8 M), which were compatible with the features of antibody of insulin autoimmune syndrome (IAS). However, hypoglycaemia was not noted throughout the course of treatment. Since the insulin binding ratio of the antibody decreased from 87.3% to 62% after the termination of insulin treatment, it was suggested that the antibody reacted mainly to exogenously injected insulin. Switching insulin preparations or introducing insulin secretagogues did not improve elevated blood glucose levels. The initiation of brentuximab vedotin (BV), a therapeutic agent for relapsed HL, resulted in a remarkable improvement in glycaemic control despite the absence of insulin therapy and partial remission of HL. This case suggested that HL triggered anti-insulin antibody production, which resulted in poor glycaemic control, and that BV could be a new treatment option for autoimmune diseases associated with HL.
- 16 October 2021
- Published by Springer Nature in Diabetology International
- Vol. 13 (2) , 456-460
Open AccessProduction of insulin antibody associated with relapsed hodgkin’s lymphoma
A 72-year-old man with type 2 diabetes mellitus with good glucose control for 20 years and maintained on oral hypoglycaemic agents was diagnosed with Hodgkin’s Lymphoma (HL) and started on insulin glargine for glycaemic control. Despite increased doses of insulin, his blood glucose levels went up dramatically. The anti-insulin antibody test proved to be positive, and Scatchard plot analysis showed 2 binding sites with relatively low-affinity constants: K1 = 0.0032, K2 = 0.0002 (108/M); and high binding capacities: R1 = 98.4, R2 = 372 (10−8 M), which were compatible with the features of antibody of insulin autoimmune syndrome (IAS). However, hypoglycaemia was not noted throughout the course of treatment. Since the insulin binding ratio of the antibody decreased from 87.3% to 62% after the termination of insulin treatment, it was suggested that the antibody reacted mainly to exogenously injected insulin. Switching insulin preparations or introducing insulin secretagogues did not improve elevated blood glucose levels. The initiation of brentuximab vedotin (BV), a therapeutic agent for relapsed HL, resulted in a remarkable improvement in glycaemic control despite the absence of insulin therapy and partial remission of HL. This case suggested that HL triggered anti-insulin antibody production, which resulted in poor glycaemic control, and that BV could be a new treatment option for autoimmune diseases associated with HL.
- 12 January 2021
- Published by Springer Nature
- Vol. 5 (1) , 61-65
Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma
T(11;22)(q13;q11)/CCND1-IGL resulted in truncation of the CCND1 3′ coding sequences in a case of blastoid variant mantle cell lymphoma. The translocation generated CCND1 with a C-terminal alteration, leading to negative CCND1 immunohistochemistry by SP4 monoclonal antibody.
- 12 January 2021
- Published by Springer Nature
- Vol. 5 (1) , 61-65
Truncation of 3' CCND1 by t(11;22) leads to negative SP4 CCND1 immunohistochemistry in blastoid mantle cell lymphoma
T(11;22)(q13;q11)/CCND1-IGL resulted in truncation of the CCND1 3′ coding sequences in a case of blastoid variant mantle cell lymphoma. The translocation generated CCND1 with a C-terminal alteration, leading to negative CCND1 immunohistochemistry by SP4 monoclonal antibody.
- Open Access
- 2 June 2020
- Published by Wiley in Clinical Case Reports
- Vol. 8 (8) , 1553-1559
Resolution of bone, cutaneous, and muscular involvement after haploidentical hematopoietic stem cell transplantation followed by post‐transplant cyclophosphamide in adult T‐cell leukemia/lymphoma
Haploidentical hematopoietic stem cell transplantation followed by post‐transplant cyclophosphamide provides a well‐tolerated and potentially curable treatment for chemorefractory acute‐type adult T‐cell leukemia/lymphoma.
- 2 June 2020
- Published by Wiley in Clinical Case Reports
- Vol. 8 (8) , 1553-1559
Open AccessResolution of bone, cutaneous, and muscular involvement after haploidentical hematopoietic stem cell transplantation followed by post‐transplant cyclophosphamide in adult T‐cell leukemia/lymphoma
Haploidentical hematopoietic stem cell transplantation followed by post‐transplant cyclophosphamide provides a well‐tolerated and potentially curable treatment for chemorefractory acute‐type adult T‐cell leukemia/lymphoma.
- Open Access
- 25 December 2019
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 22 (2) , 54-62
Amplification of the MYC gene in immunoglobulin light chain (AL) amyloidosis
We report a woman in her sixties who presented with cardiac involvement of immunoglobulin light chain (AL) amyloidosis, which was categorized into stage IV disease according to the revised Mayo clinic staging scheme. There were no myeloma-defining events at presentation. Although no M-protein was found in the serum, Bence-Jones protein κ was detected in the urine by immunofixation. The bone marrow showed hypocellularity but contained 25.6% plasma cells by examination of aspirate smears, and the cells exhibited cytoplasmic κ light chain restriction by flowcytometry and immunohistochemistry. Fluorescence in situ hybridization and G-banding revealed t(11;14)(q13;q32), leading to the generation of the CCND1-immunoglobulin heavy chain fusion gene. We obtained metaphase spreads that contained a homogeneous staining region on chromosome 8 at band q24, where multiple copies of the MYC gene were localized. However, the majority of interphase nuclei carried 2 or 3 copies of MYC and only occasional cells had four or more MYC signals, suggesting that MYC amplification occurred in a fraction of neoplastic cells. It is therefore possible that the MYC amplification represented intraclonal genetic heterogeneity and diverse subclones in terms of the copy number of MYC were present at presentation.
- 25 December 2019
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 22 (2) , 54-62
Open AccessAmplification of the MYC gene in immunoglobulin light chain (AL) amyloidosis
We report a woman in her sixties who presented with cardiac involvement of immunoglobulin light chain (AL) amyloidosis, which was categorized into stage IV disease according to the revised Mayo clinic staging scheme. There were no myeloma-defining events at presentation. Although no M-protein was found in the serum, Bence-Jones protein κ was detected in the urine by immunofixation. The bone marrow showed hypocellularity but contained 25.6% plasma cells by examination of aspirate smears, and the cells exhibited cytoplasmic κ light chain restriction by flowcytometry and immunohistochemistry. Fluorescence in situ hybridization and G-banding revealed t(11;14)(q13;q32), leading to the generation of the CCND1-immunoglobulin heavy chain fusion gene. We obtained metaphase spreads that contained a homogeneous staining region on chromosome 8 at band q24, where multiple copies of the MYC gene were localized. However, the majority of interphase nuclei carried 2 or 3 copies of MYC and only occasional cells had four or more MYC signals, suggesting that MYC amplification occurred in a fraction of neoplastic cells. It is therefore possible that the MYC amplification represented intraclonal genetic heterogeneity and diverse subclones in terms of the copy number of MYC were present at presentation.
- Open Access
- 25 December 2018
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 21 (2) , 56-69
Serum free light chain-only multiple myeloma associated with multiple bone involvement and the t(11;14)(q13;q32)/CCND1-immunoglobulin heavy chain fusion gene: A report of three cases
We herein report three cases of multiple myeloma (MM), in which no M component was detected in serum or urine; however, the serum free light chain (sFLC) assay showed an excess of sFLC-κ and a high κ/λ ratio. The first case was a man in his fifties with multiple osteolytic lesions and hypercalcemia. The immunofixation of serum revealed no M component and urinary protein was below the detection level, while sFLC-κ was 10,700.0 mg/L (reference range, 3.3 to 19.4 mg/L) and the κ/λ ratio was 672.96 (reference range, 0.26 to 1.65). Although he responded to bortezomib and dexamethasone followed by high-dose melphalan with autologous hematopoietic stem cell transplantation, he relapsed with the features of plasma cell leukemia. The second case was a woman in her forties with multiple bone involvement. The immunofixation of serum and urine was negative, while sFLC-κ was 1,610.0 mg/L and the κ/λ ratio was 217.57. She was treated with bortezomib, lenalidomide, and dexamethasone. The third case was a woman in her seventies with paraplegia due to a vertebral tumor. Immunofixation was negative, sFLC-κ was 1580.0 mg/L, and the κ/ λ ratio was 141.07. Bone marrow in each case contained 63.8, 39.8, and 7.4% myeloma cells in which the κ light chain was expressed in the cytoplasm, as revealed by multicolor flow cytometry. Fluorescence in situ hybridization of myeloma cell nuclei revealed the presence of the CCND1-immunoglobulin heavy chain fusion gene (IGH) indicative of t(11;14)(q13;q32), but showed variant hybridization signal patterns. These three cases matched the criteria of recently proposed sFLC-only MM and were characterized by multiple bone involvement, the lack of significant anemia and impaired renal function, an immature myeloma cell morphology, and the CCND1-IGH fusion gene. These results support the routine use of the sFLC assay for a work-up when a patient is suspected of having a plasma cell disorder.
- 25 December 2018
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 21 (2) , 56-69
Open AccessSerum free light chain-only multiple myeloma associated with multiple bone involvement and the t(11;14)(q13;q32)/CCND1-immunoglobulin heavy chain fusion gene: A report of three cases
We herein report three cases of multiple myeloma (MM), in which no M component was detected in serum or urine; however, the serum free light chain (sFLC) assay showed an excess of sFLC-κ and a high κ/λ ratio. The first case was a man in his fifties with multiple osteolytic lesions and hypercalcemia. The immunofixation of serum revealed no M component and urinary protein was below the detection level, while sFLC-κ was 10,700.0 mg/L (reference range, 3.3 to 19.4 mg/L) and the κ/λ ratio was 672.96 (reference range, 0.26 to 1.65). Although he responded to bortezomib and dexamethasone followed by high-dose melphalan with autologous hematopoietic stem cell transplantation, he relapsed with the features of plasma cell leukemia. The second case was a woman in her forties with multiple bone involvement. The immunofixation of serum and urine was negative, while sFLC-κ was 1,610.0 mg/L and the κ/λ ratio was 217.57. She was treated with bortezomib, lenalidomide, and dexamethasone. The third case was a woman in her seventies with paraplegia due to a vertebral tumor. Immunofixation was negative, sFLC-κ was 1580.0 mg/L, and the κ/ λ ratio was 141.07. Bone marrow in each case contained 63.8, 39.8, and 7.4% myeloma cells in which the κ light chain was expressed in the cytoplasm, as revealed by multicolor flow cytometry. Fluorescence in situ hybridization of myeloma cell nuclei revealed the presence of the CCND1-immunoglobulin heavy chain fusion gene (IGH) indicative of t(11;14)(q13;q32), but showed variant hybridization signal patterns. These three cases matched the criteria of recently proposed sFLC-only MM and were characterized by multiple bone involvement, the lack of significant anemia and impaired renal function, an immature myeloma cell morphology, and the CCND1-IGH fusion gene. These results support the routine use of the sFLC assay for a work-up when a patient is suspected of having a plasma cell disorder.
- 1 January 2017
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 20 (2) , 115-118
Intractable hemorrhage from the site of bone marrow aspiration and trephine biopsy
- 1 January 2017
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 20 (2) , 115-118
Intractable hemorrhage from the site of bone marrow aspiration and trephine biopsy
- 17 March 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (11) , 2593-2602
A unique subtype of diffuse large B-cell lymphoma primarily involving the bone marrow, spleen, and liver, defined by fluorodeoxyglucose-positron emission tomography combined with computed tomography
We describe 10 cases of diffuse large B-cell lymphoma (DLBCL) confined to the bone marrow (BM), spleen, and liver, as evidenced by the uniformly increased uptake of fluorodeoxyglucose (FDG) on positron emission tomography combined with computed tomography (PET/CT). Ages ranged from 56 to 87. All, but one patient presented with ‘B’ symptoms, a poor performance status, and hepatosplenomegaly. All patients showed cytopenia and elevated lactate dehydrogenase levels and were classified into the high-risk category of the International Prognostic Index scoring. BM infiltration was diffuse, interstitial/intrasinusoidal, or mixed, and all showed the nongerminal center B immunophenotype. Five patients had a rearrangement involving 3q27/BCL6, while six had increased copies of MYC, BCL2, or BCL6. All patients were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, leading to complete responses in six out of eight evaluable patients. We propose BM, spleen, and liver-type DLBCL, which is defined by the findings of FDG-PET/CT.
- 17 March 2016
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 57 (11) , 2593-2602
A unique subtype of diffuse large B-cell lymphoma primarily involving the bone marrow, spleen, and liver, defined by fluorodeoxyglucose-positron emission tomography combined with computed tomography
We describe 10 cases of diffuse large B-cell lymphoma (DLBCL) confined to the bone marrow (BM), spleen, and liver, as evidenced by the uniformly increased uptake of fluorodeoxyglucose (FDG) on positron emission tomography combined with computed tomography (PET/CT). Ages ranged from 56 to 87. All, but one patient presented with ‘B’ symptoms, a poor performance status, and hepatosplenomegaly. All patients showed cytopenia and elevated lactate dehydrogenase levels and were classified into the high-risk category of the International Prognostic Index scoring. BM infiltration was diffuse, interstitial/intrasinusoidal, or mixed, and all showed the nongerminal center B immunophenotype. Five patients had a rearrangement involving 3q27/BCL6, while six had increased copies of MYC, BCL2, or BCL6. All patients were initially treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone, leading to complete responses in six out of eight evaluable patients. We propose BM, spleen, and liver-type DLBCL, which is defined by the findings of FDG-PET/CT.
- 1 January 2016
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 19 (1) , 58-61
Intravascular large B-cell lymphoma diagnosed on a nasal mucosal biopsy with the guide of FDG-PET/CT imaging study
- 1 January 2016
- Published by Tenri Foundation, Tenri Institute of Medical Research in Tenri Medical Bulletin
- Vol. 19 (1) , 58-61
Intravascular large B-cell lymphoma diagnosed on a nasal mucosal biopsy with the guide of FDG-PET/CT imaging study
- 13 October 2015
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (3) , 498-505
Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy
Although the number of patients aged 80 years or older with aggressive B-cell non-Hodgkin lymphoma (B-NHL) has increased in the clinical setting, management has been challenging due to lower tolerability. The aim of the present study was to evaluate the efficacy and safety of reduced-dose chemotherapy for very elderly patients. We retrospectively analyzed the clinical outcomes of patients aged ≥80 years old with diffuse large B-cell lymphoma (n = 58) or grade 3 follicular lymphoma (n = 3). Patient ages ranged from 80 to 93 years old, with a median of 83 years old. Twenty-four patients were treated with CHOP or THP-COP, the dosages of which were variably reduced, in combination with rituximab (R-vCHOP), while another 24 patients were treated with R-miniCHOP. Twelve R-vCHOP and 16 R-miniCHOP patients completed the chemotherapy cycles. The estimated 2-year progression-free and overall survival rates in the R-vCHOP and R-miniCHOP groups were 53 and 39 % (P = 0.92) and 53 and 48 % (P = 0.95), respectively. Performance status ≥2, lactate dehydrogenase level >normal, serum albumin ≤3.5 g/dL, C-reactive protein ≥2.0 mg/dL, age-adjusted International Prognostic Score 2/3, and withdrawal from the chemotherapy cycle were associated with poor survival. The frequency of chemotherapy-related hospitalization during the second or later cycles was significantly less in the R-miniCHOP group. The efficacies of R-vCHOP and R-miniCHOP were similar in patients aged ≥80 years old with aggressive B-NHL. The reduced frequency of hospitalization observed for R-miniCHOP treatment is beneficial for very elderly patients.
- 13 October 2015
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (3) , 498-505
Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy
Although the number of patients aged 80 years or older with aggressive B-cell non-Hodgkin lymphoma (B-NHL) has increased in the clinical setting, management has been challenging due to lower tolerability. The aim of the present study was to evaluate the efficacy and safety of reduced-dose chemotherapy for very elderly patients. We retrospectively analyzed the clinical outcomes of patients aged ≥80 years old with diffuse large B-cell lymphoma (n = 58) or grade 3 follicular lymphoma (n = 3). Patient ages ranged from 80 to 93 years old, with a median of 83 years old. Twenty-four patients were treated with CHOP or THP-COP, the dosages of which were variably reduced, in combination with rituximab (R-vCHOP), while another 24 patients were treated with R-miniCHOP. Twelve R-vCHOP and 16 R-miniCHOP patients completed the chemotherapy cycles. The estimated 2-year progression-free and overall survival rates in the R-vCHOP and R-miniCHOP groups were 53 and 39 % (P = 0.92) and 53 and 48 % (P = 0.95), respectively. Performance status ≥2, lactate dehydrogenase level >normal, serum albumin ≤3.5 g/dL, C-reactive protein ≥2.0 mg/dL, age-adjusted International Prognostic Score 2/3, and withdrawal from the chemotherapy cycle were associated with poor survival. The frequency of chemotherapy-related hospitalization during the second or later cycles was significantly less in the R-miniCHOP group. The efficacies of R-vCHOP and R-miniCHOP were similar in patients aged ≥80 years old with aggressive B-NHL. The reduced frequency of hospitalization observed for R-miniCHOP treatment is beneficial for very elderly patients.
- Open Access
- 30 October 2014
- Published by Wiley in Haemophilia
- Vol. 20 (6) , e402-e404
Long‐term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor
- 30 October 2014
- Published by Wiley in Haemophilia
- Vol. 20 (6) , e402-e404
Open AccessLong‐term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor